30 million consumers have taken DTC genetic tests. 1 in 10 Americans will have taken a genetic test by 2020.

42K tests completed per day, many with actionable genes and/or FDA clearance.

People of European descent:
- 10% of the world’s population
- 78% of genetic study participants

Populations not of European descent remain largely underrepresented in biomedical research.

>268,000 participants, out of the one million person target have enrolled in the all of us research program.

AMA Precision Medicine Efforts:
- 40+ internal policies
- 10+ years of research
- 30+ CME educational courses

Over 75,000 genetic tests offered. 10 new tests are introduced per day, along with growth in prior authorization.

Expected findings from genomic screening in healthy populations:
- >3% have clinically actionable or pathogenic variants
- 55/59 genes have autosomal dominant inheritance, impacting cascade screening
- >30% have findings of note considered "nonactionable"
- >90% are carriers of inherited autosomal recessive disorders
- >95% have actionable pharmacogenomic variants

Legislative, legal, and regulatory landscape for genetic tests:
- FDCA 1976
- CLIA 1988
- HIPAA 1996
- NYSDOH 2005
- GINA 2008
- AMP vs. Myriad 2013
- PAMA 2014
- FDA Draft Guidances - LDTs 2014
- 21st Century Cures Act 2016
- VALID Act Draft 2018